EyePoint sells remaining rights to eye implant, pivots to tackle anti-VEGFs

Paul Schloesser

Associate Editor

EyePoint is selling off the remaining global rights to its intravitreal implant Yutiq to Alimera, another eye-focused biotech, for $82.5 million.

EyePoint Pharmaceuticals announced Thursday that Alimera will receive global rights to Yutiq except in China, Hong Kong, Taiwan, Macau and Southeast Asia. EyePoint, in 2018, granted an exclusive license to Ocumension Therapeutics, a Chinese biotech in those markets. EyePoint continues to receive royalties from those sales — and expects to keep them for at least the next decade.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

EyePoint sells remaining rights to eye implant, pivots to tackle anti-VEGFs

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Data Quality 2.0: The Future of Real-World Evidence

Eye­Point sells re­main­ing rights to eye im­plant, piv­ots to tack­le an­ti-VEG­Fs

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

EyePoint sells remaining rights to eye implant, pivots to tackle anti-VEGFs

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Madrigal raises $500M for NASH drug launch, discloses cyberattack

Data Quality 2.0: The Future of Real-World Evidence